-
Parmax Pharma Announces Positive Results from Phase 2a Trial of PAR-003 for the Treatment of Alopecia Areata
Parmax Pharma Limited (AIM: PRMX), a specialty pharmaceutical company focused on the development and commercialization of innovative proprietary products for the treatment of dermatological conditions, today announces positive top-line results from its Phase 2a clinical trial evaluating the safety and efficacy of PAR-003 for the treatment of alopecia areata.
-
Parmax Pharma Licenses Exclusive Worldwide Rights to Develop and Commercialize Anti-Inflammatory Drug Candidate for Dermatological Conditions
Parmax Pharma Limited (AIM: PRMX), a specialty pharmaceutical company focused on the development and commercialization of innovative proprietary products for the treatment of dermatological conditions, today announces that it has entered into an exclusive worldwide license agreement with a leading global pharmaceutical company to develop and commercialize a novel anti-inflammatory drug candidate for the treatment of dermatological conditions.
-
Parmax Pharma Announces Positive Preclinical Data for PAR-004, a Novel Topical Treatment for Atopic Dermatitis
Parmax Pharma Limited (AIM: PRMX), a specialty pharmaceutical company focused on the development and commercialization of innovative proprietary products for the treatment of dermatological conditions, today announces positive preclinical data for PAR-004, a novel topical treatment for atopic dermatitis.
-
Parmax Pharma Granted US Patent for PAR-003, a Novel Treatment for Alopecia Areata
Parmax Pharma Limited (AIM: PRMX), a specialty pharmaceutical company focused on the development and commercialization of innovative proprietary products for the treatment of dermatological conditions, today announces that the United States Patent and Trademark Office (USPTO) has granted the Company a patent for PAR-003, its novel topical treatment for alopecia areata.
-
Parmax Pharma Announces Positive Top-Line Results from Phase 2b Trial of PAR-001 for the Treatment of Moderate-to-Severe Plaque Psoriasis
Parmax Pharma Limited (AIM: PRMX), a specialty pharmaceutical company focused on the development and commercialization of innovative proprietary products for the treatment of dermatological conditions, today announces positive top-line results from its Phase 2b clinical trial evaluating the safety and efficacy of PAR-001 for the treatment of moderate-to-severe plaque psoriasis.
-
Parmax Pharma Announces Positive Results from Phase 2a Trial of PXT3003 in Idiopathic Pulmonary Fibrosis
Parmax Pharma Limited (AIM: PRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for respiratory diseases, today announced positive results from a Phase 2a trial evaluating the safety and efficacy of PXT3003 in patients with idiopathic pulmonary fibrosis (IPF).
-
Parmax Pharma Announces FDA Clearance of IND Application for PXT864 for the Treatment of Moderate-to-Severe Asthma
Parmax Pharma Limited (AIM: PRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for respiratory diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PXT864, a novel, inhaled, once-daily, dual bronchodilator for the treatment of moderate-to-severe asthma.
-
Parmax Pharma Announces Encouraging Preclinical Data for PXT3003 in Idiopathic Pulmonary Fibrosis
Parmax Pharma Limited (AIM: PRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for respiratory diseases, today announced encouraging preclinical data for PXT3003, a novel, inhaled, once-daily therapy for the treatment of idiopathic pulmonary fibrosis (IPF).